398 related articles for article (PubMed ID: 26959061)
1. Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice.
Scaglione F
Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26959061
[TBL] [Abstract][Full Text] [Related]
2. Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions.
Ozer IS; Kuzu Kumcu M; Tezcan Aydemir S; Akbostanci MC
Clin Neurol Neurosurg; 2021 Oct; 209():106889. PubMed ID: 34461363
[TBL] [Abstract][Full Text] [Related]
3. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
[TBL] [Abstract][Full Text] [Related]
4. Safety profile of incobotulinum toxin A [Xeomin(®)] in gastrocnemious muscles injections in children with cerebral palsy: Randomized double-blind clinical trial.
Carraro E; Trevisi E; Martinuzzi A
Eur J Paediatr Neurol; 2016 Jul; 20(4):532-7. PubMed ID: 27177451
[TBL] [Abstract][Full Text] [Related]
5. Conversion ratio between Dysport and Botox in clinical practice: an overview of available evidence.
Ravenni R; De Grandis D; Mazza A
Neurol Sci; 2013 Jul; 34(7):1043-8. PubMed ID: 23576131
[TBL] [Abstract][Full Text] [Related]
6. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
[TBL] [Abstract][Full Text] [Related]
7. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.
Frevert J
Drugs R D; 2010; 10(2):67-73. PubMed ID: 20698714
[TBL] [Abstract][Full Text] [Related]
8. AbobotulinumtoxinA (Dysport
Field M; Splevins A; Picaut P; van der Schans M; Langenberg J; Noort D; Snyder D; Foster K
Toxins (Basel); 2018 Dec; 10(12):. PubMed ID: 30551641
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin A (Dysport®): in dystonias and focal spasticity.
Keam SJ; Muir VJ; Deeks ED
Drugs; 2011 May; 71(8):1043-58. PubMed ID: 21668041
[TBL] [Abstract][Full Text] [Related]
10. Clinical differences between botulinum neurotoxin type A and B.
Bentivoglio AR; Del Grande A; Petracca M; Ialongo T; Ricciardi L
Toxicon; 2015 Dec; 107(Pt A):77-84. PubMed ID: 26260691
[TBL] [Abstract][Full Text] [Related]
11. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
Bihari K
Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
[TBL] [Abstract][Full Text] [Related]
12. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
Wissel J; Entner T
Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
[TBL] [Abstract][Full Text] [Related]
13. Botulinum neurotoxin type A-ABO (Dysport): clinical indications and practice guide.
Matarasso A; Shafer D
Aesthet Surg J; 2009 Nov; 29(6 Suppl):S72-9. PubMed ID: 19945008
[TBL] [Abstract][Full Text] [Related]
14. The setting of a botulinum toxin treatment service.
Cavallini M
Neurol Sci; 2014 May; 35 Suppl 1():49-50. PubMed ID: 24867836
[TBL] [Abstract][Full Text] [Related]
15. [Use of botulinum neurotoxin therapy].
Mukai Y; Kaji R
Brain Nerve; 2011 Jul; 63(7):775-84. PubMed ID: 21747148
[TBL] [Abstract][Full Text] [Related]
16. The broadening application of chemodenervation in X-linked dystonia-parkinsonism (Part II): an open-label experience with botulinum toxin-A (Dysport®) injections for oromandibular, lingual, and truncal-axial dystonias.
Rosales RL; Ng AR; Santos MM; Fernandez HH
Int J Neurosci; 2011; 121 Suppl 1():44-56. PubMed ID: 21348790
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia.
Kazerooni R; Broadhead C
Am J Health Syst Pharm; 2015 Feb; 72(4):301-7. PubMed ID: 25631837
[TBL] [Abstract][Full Text] [Related]
18. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.
Jost WH; Blümel J; Grafe S
Drugs; 2007; 67(5):669-83. PubMed ID: 17385940
[TBL] [Abstract][Full Text] [Related]
19. Significant Long-Lasting Improvement after Switch to Incobotulinum Toxin in Cervical Dystonia Patients with Secondary Treatment Failure.
Hefter H; Ürer B; Brauns R; Rosenthal D; Meuth SG; Lee JI; Albrecht P; Samadzadeh S
Toxins (Basel); 2022 Jan; 14(1):. PubMed ID: 35051021
[TBL] [Abstract][Full Text] [Related]
20. Dysport (botulinum toxin type A) in routine therapeutic usage: a telephone needs assessment survey of European physicians to evaluate current awareness and adherence to product labeling changes.
Hubble J; Schwab J; Hubert C; Abbott CC
Clin Neuropharmacol; 2013; 36(4):122-7. PubMed ID: 23783005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
